The Tianyang Pharmaceuticals Company in Tianchang in China's Anhui province plans to invest 12 million renminbi ($1.44 million) in 1997 in the installation of a new line for the production of 10 million bottles of infusions a year, according to China Foreign Trade. Next year, the firm expects to achieve an output value of 100 million renminbi, and a profit of 10 million renminbi. 1n 1998, it will invest 15 million renminbi in the setting up of a line producing 100 million units of powdered pharmaceuticals, which will increase the firm's total output of 160 million renminbi.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze